StocksMedium•9 November 2026•
1 min read
Lantheus to Sell CDMO Business and New Jersey Facility to PharmaLogic
Key Facts
1Lantheus signed a definitive agreement to sell its CDMO business and Springfield, New Jersey manufacturing facility to PharmaLogic.
Lantheus signed a definitive agreement to sell its contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey manufacturing facility to PharmaLogic. PR Newswire reported that the deal allows PharmaLogic to expand its U.S. therapeutic manufacturing capacity and establish a transatlantic CDMO platform for radioligand therapies.
Lantheus stock, trading under the ticker LNTH, closed at $100.61 on November 6, 2026. During that session, the stock reached a high of $101.02 and a low of $100.4 before the announcement of the divestment, which is expected to streamline the company's operations.